Eliglustat

CAS : 491833-29-5

Ref. 3D-FD158477

Informations sur le produit

• Nom: Eliglustat
• Synonymes: N-[(1R,2R)-2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl]octanamide

Description

Eliglustat is an investigational drug for the treatment of hepatic steatosis. Eliglustat is a complex enzyme inhibitor that blocks the synthesis of glucosylceramide and prevents the accumulation of lipids in the liver. It has been shown in animal studies to have long-term efficacy in preventing hepatic steatosis and improving disease activity. The median plasma concentration of eliglustat is approximately 1,000 times higher than other drugs that inhibit glucosylceramide synthesis. Although eliglustat has not been approved by the FDA, it has been shown to be safe and effective in clinical trials involving patients with chronic viral hepatitis B or C infection.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 404.54 g/mol
• Formule: C₂₃H₃₆N₂O₄
• Degré de pureté: Min. 97 Area-%
• Couleur/Forme: White Powder